Burning Rock Biotech (BNR) Receivables - Other (2019 - 2026)

Burning Rock Biotech's Receivables - Other history runs 8 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Receivables - Other fell 22.14% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (down 22.14% YoY), while the FY2025 annual figure was $1.8 million, down 7.32% from the prior year.
• Receivables - Other for Q1 2026 stood at $1.8 million, up from $1.7 million in the prior quarter.
• The five-year high for Receivables - Other was $32.1 million in Q2 2022, with the low at $1.7 million in Q4 2025.
• The 5-year median for Receivables - Other is $3.2 million (2023), against an average of $5.8 million.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other surged 32972.16% in 2022, then tumbled 74.72% in 2023.
• Burning Rock Biotech's Receivables - Other stood at $5.9 million in 2022, then plunged by 46.19% to $3.2 million in 2023, then plunged by 38.95% to $1.9 million in 2024, then retreated by 10.08% to $1.7 million in 2025, then advanced by 6.26% to $1.8 million in 2026.
• Business Quant data shows BNR's Receivables - Other at $1.8 million in Q1 2026, $1.7 million in Q4 2025, and $1.8 million in Q3 2025.